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Abstract 
Children with inflammatory bowel disease (IBD) have higher rates of extraintestinal 
manifestations (EIMs) than the adult IBD population.
1
 It is believed that these manifestations are 
an extension of the autoimmune inflammatory pathology of IBD into organs of the body outside 
of the gastrointestinal system such as musculoskeletal, hepatobiliary, oral, dermatological, and 
ophthalmological systems. Secondary EIMs are systemic changes that result from inflammation 
of the gastrointestinal system. These include, weight loss and growth failure, anemia, and 
decrease in bone mineral density. EIMs can present before, during, or after gastrointestinal 
symptoms and may not necessarily be congruous with the severity of IBD flares. The goal of this 
review is to inform clinicians about the relationship between various EIMs and IBD in order to 
expedite diagnosis and treatment of IBD and its complications. This is especially important in 
the pediatric population where a delay in diagnosis affects patients’ development and future 
health. 
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Introduction 
The inflammatory bowel diseases (IBD) are comprised of the heterogeneous disorders 
Crohn’s disease (CD), ulcerative colitis (UC), and indeterminate colitis that all manifest as 
chronic inflammation of the gastrointestinal tract. For many patients, IBD does not only present 
with intestinal manifestations. Symptoms may manifest elsewhere in the gastrointestinal system 
such as oral and hepatic inflammation in addition to musculoskeletal, cutaneous, and ocular 
systems. Especially important in the pediatric population, gastrointestinal inflammation often 
results in malabsorption that may lead to constitutional symptoms such as growth failure, 
abnormal skeletal development, and anemia that often delay development and puberty. These 
symptoms in association with IBD are termed “extraintestinal manifestations” or EIM. In the 
adult IBD population, EIMs have a reported prevalence in the range between 6-42%. In the 
pediatric IBD population, this prevalence is much greater. The presentation of at least one EIM 
among pediatric IBD is 68%. According to one study, EIMs are present in 50% with UC and in 
80% with CD.
1
 In the management of pediatric IBD, it is necessary to recognize and address 
EIMs in addition to the gastrointestinal manifestations. Here we will discuss the presentation of 
EIM in the pediatric population with IBD. The first section presents current research and medical 
management of pediatric IBD. The second section presents a review of literature of common 
EIMs of pediatric IBD.  
 
Pediatric Inflammatory Bowel Disease 
Epidemiology 
In the general IBD population, the peak incidence of IBD is in the third decade but about 
25-30% of patients with CD and 20% of patients with UC present before the age of 20.
2
 In the 
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pediatric population, the peak age of onset is during late adolescence, and 4% of the pediatric 
IBD is diagnosed before the age of 5.
3 
Overall, there has been an increase in the diagnoses of 
IBD in the past century. In a study that reviewed trends of incidence of pediatric IBD from 139 
studies across 32 countries conducted from 1950 to 2009, 60% of studies reported an increase of 
incidence in CD and 65% reported no change in incidence in UC.
4
 These trends were also 
reflected in a recent 12-year study in Texas that showed an increase of incidence in CD but 
stability in incidence of UC. This study also noted that Caucasians had higher incidence 
(4.5/100,000) than African-American (1.83/100,000) or Hispanic (0.62/100,000), and that 
African-Americans had higher incidence of CD than UC. 
5
 
 
Etiology  
Although the etiology of IBD has been studied for decades, we still have little 
understanding of the initiating factors of chronic inflammation of the intestines. We know that 
the etiology is likely multifactorial due to specific genetic predispositions and environmental 
exposures that affect the immune response to the intestinal epithelium.  The pathological process 
includes a compromised intestinal epithelial barrier, microfloral invasion of the intestinal wall, 
and an exaggerated immune response. 
6
 
The hygiene hypothesis is thought to explain the increasing incidence of IBD around the 
world in past decades. This hypothesis comes from the observation that with the improvements 
of hygiene in the latter half of the 20
th
 century, we have seen an increased prevalence of diseases 
of disturbed immune function such as allergies and autoimmune diseases. Multiple factors such 
as a lower exposure to Helicobacter pylori and helminthes, widespread use of antibiotics as well 
as increased hygiene and less crowding in households are implicated in altering the microflora to 
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which individuals are exposed. This suggests that interaction with certain microorganisms in the 
environment is integral to normal immune development.
7,8
 
Another hypothesis is that IBD presents as an appropriate immunological response to an 
unknown organism, antigen, or toxin.
9 
Studies have excluded organisms such as Salmonella, 
Campylobacter jejuni, Clostridium difficile, adenoviruses, rotaviruses, and mycoplasma as 
etiological infective agents, although they may have a role in triggering an increased immune 
response in an individual predisposed to IBD. Several studies and anecdotal evidence suggest 
that Mycobacterium avium subspecies paratuberculosis (MAP) may be a possible etiological 
agent for CD.
10
 A third possibility is that there is a structural anomaly of the intestinal wall that 
allows increased immune cell exposure to gut flora.
9
 
CD is associated with increased Th1 T cell-mediated response that promotes production 
of pro-inflammatory cytokines interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-
α), IL-12 and IL-18, whereas UC is associated with atypical Natural Killer T cell and Th2 T cell-
mediated response with production of the cytokines IL-5 and IL-13. Despite these differences, 
both CD and UC share similar end-stage inflammatory pathways of intestinal injury caused by 
interaction of immune cells, inflammatory mediators, intestinal epithelium, and microflora. 
11,12 
 
Clinical Characteristics 
Symptoms that cause a high degree of suspicion of colitis are bloody stool, diarrhea, 
urgency and increased frequency of stooling, abdominal discomfort, and a presentation of 
anorexia and weight loss.
13 
Any one of these presenting symptoms may warrant consideration of 
colitis in a differential diagnosis. Clinical presentation, radiographic and endoscopic imaging and 
histological evaluation are able to distinguish 90% of cases as UC or CD. In about 10% of cases 
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diagnostic evaluation is inconclusive and a diagnosis of “indeterminate colitis” (IC) is given.14 
Upon further progression of disease or follow-up diagnostic evaluation, about 90% of IC cases 
are able to be distinguished as UC or CD, but 10% of cases retain the diagnosis of IC. 
15
 
Gastrointestinal manifestations of UC by definition are limited to the large intestine. The 
natural progression of disease begins in the rectum and extends proximally in a continuous 
pattern along the colon. Extent of disease is measured by the extent of colon involved and the 
severity of inflammation of the mucosal layer. Pain in the left lower quadrant may reflect either 
distal disease that involves the rectum or rectosigmoid colon, or left-sided disease that involves 
the rectum, sigmoid, and descending colon. Pain extending to the entire abdomen may reflect 
pancolitis that involves the entire colon. In children with UC, 15-22% present with 
rectosigmoidal disease, 22-36% have left-sided disease, and 43-63% present with pancolitis.
16
 
Inflammation of the colon is appreciated on colonoscopy characterized by hyperemia, edema, 
granularity with easy friability and superficial ulcerations limited to the mucosal layer. Islands of 
mucosal regeneration bulge up between the ulcers to form pseudopolyps. If the muscularis 
propria becomes exposed to the bacteria of colonic lumen, perforation and pericolonic abscesses 
may form. Further involvement of the neural plexus in the muscularis propria causes dilation, 
edema and gangrene of the colon, termed toxic megacolon.
17
 Patients with UC are at higher risk 
for colon cancer. Pancolectomy is preventative against colon cancer and curative for UC, yet 
requires a lifestyle change of managing a permanent stoma.
18
  
Unlike UC that is limited to the colon, inflammatory lesions in CD may present anywhere 
along the gastrointestinal tract from the mouth to the anus, but most commonly affects the 
terminal ileum. Aphthous mouth ulcers and perianal disease (skin tags, fissures, abscesses, or 
fistulas) are specific symptoms of CD that are not seen in UC. CD lesions are classically discrete 
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“skip lesions” with unaffected healthy tissue between lesions, but may coalesce to create large 
lesions that resemble those of UC. Unlike UC, CD lesions can affect the entire thickness of 
bowel wall forming transmural noncaseating granulomas, fissures, strictures, and fistulas. Failure 
to thrive or weight loss is more likely to be the presenting symptom in CD (85%) than in UC 
(65%), but is present in a majority of cases in both types of IBD.
 19 
CD refractory to medication 
may be treated with surgery, but unlike UC, resection is palliative and not curative because 
another part of the gastrointestinal tract may be affected after resection.
17
 
A meta-analysis of 14 pediatric studies of 1153 children with CD found that 38% of cases 
had isolated ileal disease, 38% had both ileal and colonic disease, and 20% had isolated colonic 
disease.
 20 In Mamula’s study of children 5 years of age and younger it was found that isolated 
ileal disease was less common (11% of cases) than among older children, and had higher 
involvement of the colon with mixed ileal and colonic disease in 59% of cases and isolated 
colonic disease in 30% of cases.
21
 Perianal disease is present in 11-18% of children with CD, but 
is more common among children under 5 years of age at 34% which is similar to that of the rate 
among the adult population (36-46%).
22 
 
Diagnostics 
Before diagnosing IBD, other more common causes of presenting symptoms such as 
bloody diarrhea or weight loss must be ruled out. First, a hemoccult stool test is performed to 
detect the presence of blood in stool. Further, stool cultures are taken to screen for common 
infectious gastroenteritis pathogens such as enteropathogenic E. coli, Yersinia entercolitica, 
Campylobacter jejuni, Salmonella, Shigella, Entamoeba histolytica, Giardia lamblia, 
Dientamoeba fragilis, Mycobacterium tuberculosis, Clostridium difficile in addition to ova and 
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parasites. Blood samples are also taken to evaluate degree of disease and differential diagnoses. 
A complete blood count with differential as well as a coagulation panel help assess possible 
anemia and bleeding tendency. Further, a comprehensive metabolic panel, liver enzymes and 
protein and albumin levels, gives information on the patient’s nutritional status as well as liver 
function. Low levels of vitamin B12, folate, selenium and zinc also reflect the degree of 
malabsorption that may support a diagnosis of IBD. Blood markers of elevated erythrocyte 
sedimentation rate (ESR), fibrinogen and C-reactive protein (CRP) indicate present 
inflammation, and elevated orosomucoid is specific for CD. Further, increased levels of 
calprotectin in stool also indicates inflammation of the intestines.
 13
  
Locating affected regions of inflamed bowel by radiological imaging can be appreciated 
by thickening of luminal wall on abdominal ultrasound (US) or computed tomography (CT), but 
is most readily seen on magnetic resonance enterography (MRE) with contrast. In the pediatric 
population, MRE is the best radiographic imaging modality to detect small intestinal 
involvement but magnetic resonance (MR) colonoscopy as of yet has no role in diagnostics for 
pediatric IBD. The gold standard for diagnosis of IBD is gross inspection of the gastrointestinal 
tract upon endoscopy and colonoscopy with biopsy for histological evaluation. For the small 
bowel that cannot be seen by endoscopy or colonoscopy, wireless capsule endoscopy (WCE) is 
passed through the bowels to image the small intestine. Before administration of the WCE, 
patency capsules should be used to evaluate the risk of retention.
63
 Further distinction between 
CD or UC may be eludicated by blood serology where elevated levels of ASCA (anti-
Saccharomyces cerevisiae antibodies) suggest a diagnosis of CD and elevated levels of p-ANCA 
(perinuclear antineutrophil cytoplasmic antibody) suggest a diagnosis of UC, yet review of the 
literature suggest that these serological markers may not be reliable.
64
 Since colonic involvement 
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is more likely in children with early onset, colonoscopy is indicated first. If negative then UC is 
unlikely and an upper-GI endoscopy is performed to search for lesions indicative of CD or any 
other pathology. 
 
Treatment 
Treatment for IBD is determined by the severity, location, and type of inflammation 
taking into account the age of the patient and presence of extraintestinal manifestations. 
Presentation of acute flares of any severity is most effectively treated with a combination of 
bowel rest (supplemented with parental nutrition or clear fluids) as well as corticosteroid therapy 
to induce remission. Mild disease can often be controlled with the 5-aminosalicylic acid (5-ASA) 
anti-inflammatory agents such as sulfasalazine or mesalamine, as well as antibiotics such as 
metronidazole. For moderate disease, induction with bowel rest and corticosteroids is started 
with maintenance of immunomodulating agents such as azathioprine (AZA), 6-mercaptopurine 
(6-MP), or methotrexate. These agents are antimetabolites and interfere in the replication of 
proliferating cells, such as autoimmune T-cells. For severe disease, induction and maintenance is 
most effective with biologic agents that have anti-TNFα properties such as infliximab, 
adalimumab, certolizumab, and natalizumab. 
Side effects of these drugs are numerous and measures should be taken to prevent serious 
complications from these therapies. Folic acid should be supplemented in patients with IBD not 
only due to antimetabolic effects of IBD therapies but also due to malabsorption of vitamin B12 
and folate. Anytime a patient is on high-dose steroids, it is recommended that a proton pump 
inhibitor be also administered to protect gastric mucosa. Before administering AZA or 6-MP, it 
is helpful to measure the thiopurine methyltransferase (TPMT) enzyme activity that indicates the 
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ability to prevent the build up of cytotoxic metabolites of 6-MP. Patients with low TPMT 
enzyme activity are at a higher risk for myelosuppression, bleeding, infection, and death at 
standard doses of AZA or 6MP, and therefore these agents are not used as therapy, or if 
necessary, only used at low-dose regimens.
 23-24
 Before administering any immunosuppressing 
therapy, especially biologics, it is necessary to screen and treat any latent infections, specifically 
tuberculosis, EBV (Epstein Barr virus), and JCV (John Cunningham virus) to prevent activation 
of the infection. Further, it has been reported that concurrent therapy of AZA or 6-MP with a 
biologic therapy although effective in achieving remission in severe IBD, increases the risk of 
developing fatal hepatosplenic T-cell lymphoma. This occurs mostly in males after years of 
concurrent treatment, but can occur after just one administration of biologic therapy. 
25 
 
Extraintestinal Manifestations in Pediatric Inflammatory Bowel Disease 
Musculoskeletal Manifestations 
Arthritis is the most common extraintestinal manifestation in children with IBD occurring 
from 7-25% of cases.
26 
It is more prevalent in the pediatric than the adult IBD population with a 
higher prevalence among females.
 16, 27
 Arthritis occurs as noninfectious inflammation of joint 
synovium, seronegative for rheumatoid factor, antinuclear antibody, and LE factor.
 28 
Two 
patterns of arthritis present: peripheral and axial. Peripheral arthritis affects the joints of the 
extremities and presents as pauciarticular (type 1) or polyarticular (type 2). Both types of 
peripheral arthritis are more common in cases of CD (pauciarticular 6%, polyarticular 4%) than 
in cases of UC (pauciarticular 3.6%, polyarticular 2.5%).
29 
Pauciarticular peripheral arthritis is 
the most common presentation of arthritis in children with IBD. By definition, it affects fewer 
than 5 joints, mostly large proximal joints such as hips, knees, elbows, and ankles, often 
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asymmetrically, and is self-limiting for 5 weeks at a time. 20-40% of patients have more than 
one episode of inflammation. Pauciarticular peripheral arthritis usually reflects the disease 
activity of IBD, but may present before gastrointestinal symptoms. It has a strong association 
with HLA-B27, HLA-B35, and HLA-DR. In contrast, polyarticular peripheral arthritis by 
definition affects more than 5 joints, mostly symmetric, bilateral, and distal in the hands and feet, 
and can last for an average of 3 years. Its course is independent of IBD and does not reflect 
gastrointestinal activity. Polyarticular peripheral arthritis is associated with uveitis and HLA-B4.
1 
In Lindsley’s study of 136 children with IBD, 17% had arthritis, whereas in Passo’s study of 102 
children with IBD, 12% had arthritis, mostly commonly pauciarticular arthritis with a majority 
presenting after onset of bowel symptoms.
30-31
 
Axial arthritis is less common than peripheral arthropathy, occurring from 3-25% of 
patients with IBD. Two types of axial arthritis present: isolated sacroiliitis and ankylosing 
spondylitis that affects the vertebral column as well as the sacroiliac joints. Ankylosing 
spondylitis occurs in 5-10% of patients with IBD, most of whom are young and have HLA-B27. 
Sacroiliitis in contrast has no association with HLA-B27.
29 
Symptoms present as severe back 
pain and stiffness especially in the morning or after prolonged periods of rest. Because axial 
arthritis does not reflect gastrointestinal activity of IBD, treatment is usually directed against 
arthritis rather than IBD. Although NSAIDs are used to treat ankylosing spondylitis, in the 
presence of IBD, NSAIDs may exacerbate gastrointestinal disease. The drugs used to treat 
ankylosing spondylitis are similar to those used to treat IBD including disease-modifying 
antirheumatic drugs (DMARDs) such as sulfasalazine, mesalamine, immunosuppressants such as 
methotrexate, azathioprine, and biologic TNF-α antagonists with infliximab.1 
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Oral Manifestations 
Oral manifestations of IBD are more likely to present in the pediatric versus adult IBD 
population, in males, and in patients who have CD with involvement of proximal or perianal 
manifestations. Manifestations of IBD in the oral cavity may present as specific to either CD or 
UC, or non-specific lesions that are loosely associated with IBD. Lesions specific to CD include 
tag lesions, cobblestoning, mucogingivitis, linear ulcerations, and labial edema with fissures. 
Pyostomatitis vegetans is almost always associated with the diagnosis of IBD, notably more 
frequently in UC than in CD. Non-specific lesions include aphthous stomatitis, angular cheilitis, 
persistent submandiblar lymphadenopathy, recurrent buccal abscesses, perioral erythema with 
scaling, and glossitis.
32 
Specific CD lesions mostly affect the buccal mucosa, gingival, labial, vestibular and 
retromolar areas, usually sparing the palate, tongue and floor of the mouth. The most 
pathognomonic oral lesions of CD are oral tags and cobblestoned mucosa. Oral tags are 
epithelial folds found near the labial and buccal vestibules as well as the retromolar areas, and 
present upon histopathology with granulomas. Cobblestoned mucosa presents as firm, swollen 
micropapules with hyperplastic appearance of normal mucosal epithelium. In addition to being 
painful, these lesions may impair eating and speaking. Although oral tags and cobblestoning 
lesions do not correlate with intestinal CD activity, treatment may necessitate systemic therapy 
for CD if the lesions do not resolve with topical steroids. Mucogingivitis is also specific to CD 
presenting as edema, granulation, hyperplasia, and possible ulceration of the gingiva. It is treated 
similarly to oral tags and cobblestoning with topical steroids or systemic therapy for CD.
 32
 
Deep linear ulcerations of the buccal mucosa are an oral manifestation of CD that are 
identical histologically to the fissuring ulcers of the intestines with noncaseating granulomas 
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characterized by epithelioid histiocytes, giant cells, and lymphocytes. Unlike oral tags and 
cobblesoning lesions, these ulcerating lesions are painful to the touch and to exposure to hot, 
acidic, or spicy foods.  These ulcerations are linear, deep and persistent, unlike aphthous ulcers 
that are round, superficial, and heal within 1-2 weeks. Fissures and edema may also be present 
on the lips, and is treated similarly to deep ulcerations with topical tacrolimus and intra-lesion 
steroid injections. 
32,33
 
Pyostomatosis vegetans (PV) is a rare oral manifestation far less common than any oral 
manifestation associated with CD. PV is specific to IBD, but more commonly present in UC than 
in CD. Males are more frequently affected than females (2:1-3:1), and adults are more frequently 
affected than children.  
PV presents as multiple military white and yellow pustules scattered, clustered, or 
coalesced in a linear pattern, called “snail-track” ulcers, in an erythematous epithelium of the 
gingiva and lingual and buccal mucosa, sparing the tongue. Histological examination shows 
intra-epithelial and subepithelial microabscesses with infiltrates of neutrophils and eosinophils, 
hyperkeratosis, acanthosiss and acantholysis. Unlike in pemphigus vulgaris, immunoflorescence 
shows no deposits of IgA, IgG, or C3 deposits in PV. PV is not associated with any infective 
microorganism, and its pathogenesis still eludes researchers. Because of similar histological 
findings, it is thought that PV is the oral equivalent to pyodermatitis vegetans. The main 
laboratory finding in PV is peripheral eosinophilia which is present in 90% of cases. The 
differential diagnoses of PV include candidiasis, benign migratory glossitis, sotmatitis areata 
migrans, and pemphigus vegetans that also present with neutrophilic and eosinphilic infiltrates.  
Clinical presentation includes localized pain, enlarged and tender submandibular lymph 
nodes, and fever. About 10% of these patients also develop IBD associate arthritis of the 
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tempormandibular joint. 
33 
PV presentation may precede intestinal symptoms of UC, but mostly 
reflects the severity of intestinal UC. Systemic therapy for IBD therefore is usually needed to 
treat PV. The treatment of choice is systemic steroids because topical steroid and antiseptic 
mouthwashes are rarely effective. Azathioprine, sulfamethoxypyridazine, dapsone (second line 
in relapsing cases), cyclosporine A, biologics, and surgical colectomy are all effective options in 
treating PV and associated intestinal IBD.
32, 33 
  
Differential diagnosis of oral manifestations include reactions to foreign bodies from 
dental procedures, infections, autoimmune diseases, drug reactions, nutritional deficiencies and 
malignancies. Most foreign bodies include dental amalgams and materials. Infections that cause 
oral ulceration or granulomas include candidiasis, histioplasmosis, cryptococcosis, 
paracoccidioidomycosis, blastomycosis, in addition to tuberculosis, leprosy, cat scratch disease, 
tertiary syphilis, and hepatic infections that have other prominent features that point to diagnosis. 
Autoimmune disease that may lead to similar oral manifestations include orofacial 
granulomatosis, Behcet’s disease, Wegener’s granulomatosis, oral sarcoidosis, bullous 
pemphigoid, erythema multiforme, and epidermolysis bullosa. Nutritional deficiencies from 
malnutrition or malabsorption of vitamin B, niacin, folate, zinc can cause stomatitis, aphthous 
ulcers, glossitis, cheilitis, and perioral dermatitis. Nutritional deficiencies can be side effects 
from immunosuppressant drugs frequently used to treat IBD such as methotrexate that causes 
folate deficiency and from sulfasalazine that causes both folate and niacin deficiency. 
Orofacial granulomatosis (OFG) is a rare disease that presents with granulomatous 
cheilitis, chronic edema and fissuring of the lips, swelling of the jaw, and lesions of the gingiva 
and mucosa. Etiologically, OFG differs from oral manifestations of CD in that OGF is caused by 
infiltration of Th2 CD4+ lymphocytes whereas CD presents with infiltration of Th1 CD4 
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lymphocytes. Clinically, OFG may be identical to oral CD. Since oral CD can precede intestinal 
involvement, most diagnoses of OFG in children are found to be CD when intestinal 
inflammation presents months to years later. 
32-33 
 
Hepatobiliary Manifestions 
Patients with IBD are found to have increased risk of having primary sclerosing 
cholangitis (PSC), and autoimmune hepatitis (AIH) potentiating complications of cirrhosis, 
hepatocellular carcinoma, and liver failure. Cholelithialsis is also presents as a hepatobiliary 
manifestation, but is uncommon in children. The incidence of cholelithiasis among patients with 
CD is about 14%. This is twice the incidence of patients with UC or in the general population 
without IBD. 
34 
The overlapping syndrome of PSC with concurrent AIH is more common in the 
pediatric population than the adult population with IBD. Often clinical symptoms are identical 
and a cholangiography is needed to distinguish PSC from AIH.
 35 
Some have proposed that PSC 
is a progression of disease from AIH or are manifestations of the same disease.
36,37,38 
Whereas 
more than 80% of cases of PSC is associated with IBD especially UC, about 16% of cases of 
AIH are associated with UC.
 39 
Among patients with concurrent AIH and UC, 42% presented 
with abnormal cholangiograms suggesting an overlapping diagnosis of PSC. 
PSC is characterized by chronic inflammation and scarring of the biliary system causing 
obstruction and congestion of bile in the biliary tree. The lack of bile excretion presents with 
malabsorption of fat-soluble vitamins A, D, E, and K as well as jaundice and pruritus that reflect 
elevated levels of bilirubin. Liver damage due to congestion of bile may manifest as 
hepatomegaly, and ascites from portal hypertension and cause elevated liver enzymes.  
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Although the specific etiology of PSC is unknown, PSC is associated with various 
autoimmune diseases such as diabetes mellitus, autoimmune thyroid disease, celiac disease, 
rheumatoid arthritis. In fact, up to 25% of PSC cases versus 9% of IBD without PSC cases are 
associated with at least one other autoimmune disease. Interestingly in this study, the clinical 
presentation, outcome, and HLA alleles did not differ among groups of PSC cases with or 
without additional autoimmune diseases. In all cases of PSC, there was a significant association 
with HLD DRB1*03 compared to healthy individuals without PSC.
40 
Other findings that suggest 
that PSC is an autoimmune disease are elevated immunoglobulins, infiltration of T-lymphocytes 
in portal tracts, as well as antibodies such as anti-mitochondrial antibodies (AMA), anti-
neutrophil cytoplasmic antibodies (ANCA), anti-nuclear antibodies (ANA), smooth muscle 
antibodies (SMA), rheumatoid factor, anti-endothelial cell antibodies (AECA).
41 
These findings 
present in autoimmune diseases but have limited diagnostic value as they are not specific to PSC. 
Diagnosis of PSC is made upon a biochemical profile showing cholestasis as well as 
characteristic strictures and dilation upon cholangiography in the absence of other causes of 
sclerosing cholangitis. In the biochemical profile, alkaline phosphatase (ALP) is usually elevated 
to two to three times normal values in addition to gamma-glutamyl transpeptidase (GGT) levels. 
When the biochemical and clinical findings suggest PSC but the cholangiogram is normal, a liver 
biopsy is necessary to diagnose small-duct PSC. Those with PSC are at increased risk for 
cholangiocarcinoma seen in 7-15% of patients with PSC, diagnosed at a mean age of 45 years 
with a very poor prognosis of mean survival of 6 months. Treatment for PSC is usually with 
immunosuppressants, antifibrotics, and biologic TNF-α antagonists. Ursodeoxycholic acid has 
been studied widely with limited efficacy in treating PSC but has shown to decrease rate of 
colorectal dysplasia in patients with PSC and IBD.
42 
Treatment of PSC with immunosuppressants 
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is most effective among the pediatric population with overlapping autoimmune disease such as 
with AIH.
35, 43 
Stenting and dilatation of strictured ducts provides clinical and prognostic 
benefits. The treatment of end stage liver disease is liver transplantation, which restores biliary 
function, but does not serve as a cure since PSC can also affect the liver transplant. 
In adults with IBD, PSC is more common in UC, with a prevalence of 5% among patients 
with UC, and 3.6% among patients with CD. In adults who present with PSC, about 90% have 
concurrent IBD although intestinal symptoms may be mild. 
37 
Patients with PSC and concurrent 
UC are at higher risk for colorectal cancer than patients with UC without PSC. Therefore, it is 
prudent to perform a colonoscopy screening for IBD and colorectal cancer for all patients who 
present with PSC. Cases of PSC present twice as often in males than in females.  
In a study done by Faubion et al. of 52 children with PSC, 43 (84%) also had IBD. Of 
those patients, the 36 who could be reviewed showed 89% diagnosed with UC and 11% 
diagnosed with CD. 4% of 36 had asymptomatic IBD. This shows that PSC without IBD is rare, 
but because IBD may often be asymptomatic, children presenting with PSC should be screened 
for IBD. Further, PSC may be a marker for long-standing extensive colitis. Interestingly, IBD 
associated with PSC often presents with pancolitis with rectal sparing, whereas UC without PSC 
usually involves the rectum. It was also noted that in patients who had undergone 
proctocolectomy with ileal pouch-anal anastomosis, those who had concurrent PSC were more 
likely to have pouchitis. It is important to recognize PSC in children with IBD to optimize 
therapy and prognosis.
 44
 
Autoimmune hepatitis (AIH) is an inflammatory disease of the liver with infiltration of 
mononuclear cells and elevated serum levels of autoantibodies, immunoglobulins, and 
transaminases. Types of AIH are categorized by the associated elevated autoantibodies that 
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predominate. Type 1 AIH is defined as AIH in the presence of smooth muscle antibodies (SMA) 
or antinuclear antibodies (ANA), or both. Type 2 AIH is defined as AIH in the presence of anti 
liver kidney microsomal type 1 antibody (anti-LKM-1). Type 3 AIH is defined as AIH in the 
absence of known antibodies. Type 1 AIH accounts for 60-70% of all AIH cases and can be 
present in both adults and children, whereas type 2 AIH presents mostly in childhood. Type 2 
AIH presents more acutely and is associated with IgA deficiency. Both types 1 and 2 have 
similar clinical presentation, response to treatment, prognosis, family history of autoimmune 
disorders (40%) and association with additional autoimmune disorders (20%) and about three 
times more prevalent in females than in males. Further, both type of AIH in pediatrics have 
partial deficiency of HLA class III complement component C4. In northern Europe, HLA 
DR*0301 is present in both types of AIH, but HLA DR*0701 has a higher prevalence in type 2 
AIH. HLA DR*1301 is associated with type 1 AIH in South American pediatric population as 
well as northern European pediatric PSC population. 
45
 
Clinical presentation of AIH varies upon progression. 40% of cases present with an acute 
illness of non-specific symptoms of malaise, abdominal pain, nausea, vomiting, jaundice, that is 
common in type 2 AIH and can develop into acute hepatic failure with encephalopathy within a 
few weeks of onset. 25-40% of cases present with chronic illness of progressive fatigue, 
fluctuating headaches and jaundice, as well as loss of appetite and weight that can elude 
diagnosis for months to years. About 10% of cases show no signs of liver disease until fulminant 
liver failure. The first symptoms could be portal hypertension with ascites and esophageal 
variceal bleeding resulting in hemetemesis, hepatosplenomegaly, increase bleeding tendency, 
diarrhea, and weight loss. Regardless of the progression of presentation, most children present 
with hepatosplenomegaly and cutaneous signs of chronic liver disease such as spider nevi, 
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palmar erythema, leukonychia, and striae. Differential diagnosis of AIH include PSC, viral 
hepatitis, and Wilson’s disease.45 
AIH usually responds to immunosuppression. First line therapy is prednisolone at 
2mg/kg/day at a maximum of 60mg/day. Azathioprine is usually added later, but is not first line 
as it can cause hepatotoxicity to children who are already severely jaundiced. If steroids or 
azathioprine do not induce remission, mycophenolate mofetil and calcineurin inhibitors such as 
cyclosporine A and tacrolimus are considered as third line therapies. 
46, 47, 48 
Normalization of 
liver enzyme levels is achieved usually by 6 months for type 1 AIH and by 9 months for type 2 
AIH. Disease activity can be monitored by measuring levels of autoantibodies and IgG. Relapses 
occur in 40% of cases and are more likely before and during puberty. Relapses usually are 
treated with an increased dose of steroids. Cessation of treatment is considered only after 3 years 
since diagnosis, if liver enzyme levels have been normal for at least one year, if liver biopsies 
show no inflammation, and if the patient is not going through puberty when relapse is likely to 
occur. Remission without therapy is achieved in about 20% of cases in type 1 AIH but not in 
type 2 AIH.
45 
About 10% of patients require liver transplantation 10-15 years after diagnosis, but 
90% have favorable outcomes with normal lifestyle regardless of their presenting clinical 
symptoms, laboratory, or histological findings. 
49 
 
Dermatological Manifestations 
Skin manifestations in patients with IBD occur anywhere between 2-30% upon review of 
various studies. The most common skin manifestations are erythema nodosum (EN) and 
pyoderma gangrenosum (PG). Other cutaneous manifestations may be important red flags in 
diagnosing IBD. In addition to perianal disease that is frequent among patients with CD, 
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metastatic granulomatous tissue, while much rarer, is also specific for CD even in the absence of 
gastrointestinal manifestations. Nutritional deficiencies of zinc, vitamin B3, and vitamin C 
secondary to intestinal inflammation have reportedly caused acrodermatitis enteropathica, 
pellagra, and scurvy, respectively. These may be considered as manifestations of malabsorption 
secondary to intestinal inflammation 
50, 51 Psoriasis, Sweet’s syndrome, Steven Johnson 
syndrome, erythema multiforme, erythema elevatum diutinum, epidermolysis bullosa acquista, 
polyarteritis nodosum, and alopecia have also been reported as dermatological manifestations in 
IBD.
1, 50, 51
 
Erythema nodosum presents as tender, inflamed, nonulcerative red nodules about 1-5 cm 
in diameter that are found most commonly on the limbs especially lower leg on the anterior tibial 
area, but can also affect the trunk. Upon microscopic examination, lesions are characterized by 
lympho-histiocytic infiltrate of the lower derma, defined as septal panniculitis. EN presents in 
various infections, diseases, and reactions to medications. Infections associated with EN include 
tuberculosis (TB), coccidioidomycosis, histoplasmosis, blastomycosis, and Yersinia. EN may 
also manifest in Behçet syndrome, and sarcoidosis and as a reaction to medications such as 
sulfonamides, iodides, bromides, and estrogens. 
52
 EN is present in 4% of patients with IBD but 
has been reported in up to 15%. 
53,54
 According to Veloso, EN was reported in 8% of CD patients 
and 3% of UC patients.
55
 EN is strongly associated with CD, females, ocular and joint 
manifestations, as well as presentation of PG.
 54
 In some reports, EN is not associated with the 
severity of IBD manifestation in the intestines, but others reports that it reflects increased bowel 
inflammation.
1, 54
 Steroids, immunosuppressive therapy, potassium iodide, colchicine, 
hydroxychloroquine, and thalidomide have been used as therapy in the past but recently 
infliximab has been shown to be most effective in achieving rapid and complete resolution. 
53, 56
 
  
20 
Pyoderma gangrenosum develops first as an erythematous pustule that rapidly spreads 
and ulcerates with violaceous undermined borders that can cover an entire limb. Upon 
histological study, lesions show lymphocytic vasculitis peripherally, neutrophilic infiltration, and 
central abscess, yet the lesion is sterile. Direct immunofluorescnce demonstrates 
immunoglobulin and complement deposits in vessels of the dermis. Lesions are usually found on 
the extensor surfaces of extremities, especially below the knee, are usually multiple, and are 
more prevalent in sites of trauma.
50
 PG is reported in 0.5% to 5% of patients with IBD. About 
50% of patients with PG are found to have UC. PG is strongly associated with black African 
origin, family history of UC, pancolitis, permanent stoma, eye involvement, and EN.
 54
 
Conditions other than IBD associated with PG are myeloma, rheumatoid arthritis, and leukemia. 
Development of PG may occur before, during or after resolution of IBD symptoms. Resolution 
of mild PG can be achieved with local applications of corticosteroid, cromolyn sodium, 5-ASA. 
Other systemic agents used include sulfasalazine, dapsone, corticosteroid, immunomodulators 
(azathioprine, cyclosphosphamide, cyclosporine, methotrexate, tacrolimus, and mycophenolate 
mofetil). Most effective treatment for severe cases is infliximab.
1 
In pediatric patients with CD, the incidence of perianal disease is 13-62%. Perianal 
disease includes perianal erythema, fissures, abscesses, and complex fistulas. In a study by 
Palder, 62% of 325 children with CD studied developed perianal disease. Of those, 51% 
presented with fissures, 35% with skin tags, 15% with fistulae, and 13% with perirectal 
abscesses.
 57
 
Fissures are broad based tears in the skin near the anal opening. They are often found 
posteriorly and have undermined edges, with associated bleeding, discharge, and pruritus. 
Although anal fissures may be caused by the passing of hard stool not related to CD, in the 
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presence of CD, fissures are non-healing. Fissures reflect the activity of CD, and therefore, poor 
healing is seen with surgical attempts to suture the fissure. Most effective treatment is medical 
therapy with nitrate ointments and sitz baths.  
Skin tags are benign fleshy lobes of skin surrounding the anal opening. They are often 
associated with fissures, but are rarely painful. Excision is usually not necessary and may even 
result in poor healing and recurrence of the skin tag. 
Fistulae are patent tunnels that connect the rectum to perianal openings. Although various 
classifications are used to characterize perianal fistulae, the most common categories of 
classification are simple and complex fistulae. Simple fistulae are short tracts near the anal 
opening with no associated anal abscesses. Complex fistula may have longer tracts, branching, 
involvement of anal sphincters, with connections to the rectum above the anal sphincters and 
dermal openings farther away from the anus, and with associated abscesses. Fistulas are 
classically treated with setons that pull away surrounding tissue to allow drainage of the fistula. 
Historically, setons were pulled periodically to create a tract of healed scar tissue, but this has 
fallen out of favor due to damage to surrounding tissues that often leads to incontinence. Setons 
in conjunction with medical therapy such as antibiotics (metronidazole or ciprofloxacin), 
immunosuppressant’s and biologics are the most effective therapy. Once the inflammatory 
process of CD is treated, the seton can be removed and the tissue is able to heal properly. 
Abscesses are collections of pus that may present perianally (60%), ischiorectally (30%), 
submucosally (5%) and pelvirectally (5%). They usually appear as red swelling of the skin 
around the anus that may be firm or fluctuant, tense, and painful to the touch. They may present 
with purulent drainage from the anus or with systemic signs of fever, chills, and malaise. 
Abscesses are treated with incision and drainage, in addition to medical therapy used to treat 
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fistulas including antibiotics (metronidazole and ciprofloxacin), immunosuppressants and 
biologics. Sulfasalazine and 5-ASA have not been shown to be effective therapies.
 58
 
Metastatic Crohn’s disease (MCD), a term coined by Mountain57 in 1970 was first 
described by Park et al.
 60
 in 1965 as noncaseating granulomatous involvement of skin 
noncontinugous from the gastrointestinal tract in a patient with Crohn’s disease. These lesions 
can present as cutaneous ulcerations, plaques, papules, or nodules. Histological findings include 
multinucleated giant cells, noncaseating granulomas, perivascular lymphocytes, monocytes, and 
necrobiosis. These lesions can usually be found in skin folds such as the inframammary fold, on 
limbs, and external genitalia. 
51, 61
 20% of MCD lesions present before intestinal manifestations 
of IBD which can make diagnosis challenging because genital manifestations may be 
erroneously attributed to a gynecological or urological disorder.
61
 For example, vulvar 
inflammation may be the only presenting sign of Crohn’s disease. 61 Therapy has included zinc, 
local and systemic steroids, and immunosuppressants. 
Sweet syndrome is defined as acute febrile neutrophilic dermatosis that presents as tender 
erythematous plaques or nodules on the face, trunk and extremities. Histologically lesions reveal 
neutrophilic infiltrate with leukocytosis. A possible cause of Sweet syndrome is use of 
azathioprine in patients with CD, but resolution can be achieved with corticosteroids and 
metronidazole.
1 
 
Ophthalmological Manifestations 
 Of patients with IBD, 1.6-4.6% of patients with UC and 3-6.3% of patients with CD have 
ophthalmological involvement. Of patients with CD, ocular involvement is associated with 
involvement of the colon rather than isolated ileal disease.
 1
 It is not clearly understood whether 
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the ocular manifestations are due to an immune-complex type hypersensitivity to a colonic 
antigen, cytotoxic antibodies, or delayed-type hypersensitivity.  It is known that ocular 
manifestations often coexist with other EIMs especially arthritis and erythema nodosum, 
suggesting a common autoimmune mechanism. The most common ophthalmologic 
manifestations are episcleritis and uveitis, but also include scleritis, conjunctivitis, and rarer 
manifestations such as keratitis, retinitis, pars planitis, scleromalacia perforans, and optic 
neuritis. 
 Episcleritis is the inflammation of the episclera, the blood rich layer beneath the 
conjunctiva. Presentation involves acute redness of one or both eyes, with irritation, burning, and 
pain to palpation. Redness may be localized or diffuse around the eye, but usually spares the 
circum-limbal area. Unlike uveitis, episcleritis does not lead to loss of vision, photophobia, or 
pupillary changes. Episcleritis reflects the activity of IBD flare, and resolves with the treatment 
of the underlying IBD. For symptomatic relief, cool compresses and topical steroids may be 
used, but treatment of underlying IBD is necessary for complete resolution. 
62
 
 Uveitis is the inflammation of the vascular coat of the eye including the iris and ciliary 
body of the anterior chamber, and the vitreous, choroid and retina of the posterior chamber. 
62 
Uveitis presents as a painful eye with visual blurring, photophobia, headache, and iridospasm. 
Ciliary flush or redness at the limbus that radiates outwards is characteristic of uveitis. 
Involvement of the ciliary body and iris of the anterior chamber alters pupillary response to light 
and presents as miosis. Visual acuity is altered when inflammation presents in the posterior 
chamber.
 1, 62 
Uveitis does not reflect the gastrointestinal involvement of IBD, and therefore it is 
important to suspect IBD in patients who present with uveitis. HLA-B27 is strongly associated 
with uveitis, as well as with ankylosing spondylitis, suggesting a common underlying 
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autoimmune pathology. Diagnosis for both episcleritis and uveitis is with slit-lamp examination. 
Treatment for uveitis includes cycloplegics and topical steroids, and may necessitate systemic 
steroids or immunosupressants. 
1, 62  
 
Secondary Systemic Manifestations 
Weight loss with growth failure, anemia, as well as bone mineral density disturbances 
reflect the metabolic pathology of inflammatory of the gastrointestinal system in IBD.  
 Weight loss with growth failure is due to malnutrition and malabsorption in children with 
IBD. This may be due to too little oral intake due to fear of gastrointestinal exacerbation, nutrient 
malabsorption, or protein losing enteropathy. Impaired growth is more common in CD than in 
UC, but is common in both. Stawarski reported that 28% of children with UC and 80% of 
children with CD presented with growth delay. Insulin-like growth factor is decreased in both 
growth impaired and normally developed children with CD versus healthy controls, but studies 
have shown improvement of levels with nutritional restitution.
 26
 Frequent high dose 
corticosteroid regimens have been shown to affect type 1 collagen production that is required for 
linear growth, and therefore alternate-day regimens that have less impact on growth velocity are 
recommended especially in children. 
1
 
 Anemia is the most common hematological manifestation in IBD and according to 
Stawarski occurs in 5% of children with UC and 70% of children with CD. 
26 
Anemia is 
attributed to chronic blood loss, inadequate intake or absorption of vitamin B12 and other 
nutrients due to inflammation or resection, folate deficiency due to immunosuppressant therapy, 
or autoimmune hemolysis. Diagnosis is rapid upon routine blood tests. Therapy for anemia may 
just need vitamin supplementation or necessitate blood transfusion if symptomatic. 
1
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Decrease bone-mineral density (BMD) manifests due to malabsorption of calcium and 
vitamin D, hypogonadism , pubertal delay, low body mass index, corticosteroid exposure, and 
inflammatory cytokines involved in the IBD pathology. The spectrum of systemic skeletal 
disease is characterized by low bone density that leads to increased bone fragility and fracture. 
Measurement of BMD is presented as z-scores, or standard deviation scores in relation to 
reference values of healthy controls. Mild decrease in BMD is defined as a z-score of -1 to -2.5, 
whereas severe decrease of BMD, or osteoporosis is defined as a score lower than -2.5. Mild 
decrease in BMD is more prevalent in children with UC whereas severe decrease in BMD is 
predominant among children with CD. It is therefore recommended that children with IBD, 
especially those on high and frequent doses of steroids undergo bone densitometry every one to 
two years.
 1  
 
Conclusion 
 Inflammatory bowel disease can be a debilitating gastrointestinal disease but treating 
only gastrointestinal symptoms may be addressing only the tip of the iceberg of this disease. IBD 
is associated with many extraintestinal manifestations that can affect any organ in the body
1 
and 
therefore it is important to understand IBD as a potentially systemic disease that requires 
systemic treatment of autoimmune disturbances. Further research is needed to elucidate the 
causative mechanisms of IBD as well as its associated EIMs. Currently, it is imperative for 
pediatricians to recognize symptoms in children that can be related to IBD to diagnose and treat 
the disease to prevent any delay in growth development and restoration to health.  
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